Based on this hypothesis and our previous work10, we tested in this study the combinatory killing effects of BSO, a potent specific inhibitor of GCL in glutathione biosynthesis27, and DPI, a widely used NOX inhibitor28, on HRASG12V-transformed ovarian epithelial cells, mutant KRAS-bearing pancreatic and colon cancer cells, and murine pancreatic cancer cells harboring both KRAS and p53 mutations. The gene discussed is TP53; the disease is familial pancreatic carcinoma.